• An antifolate analog that inhibits DNA, RNA, and protein synthesis by selectively entering cells expressing RFC-1, gets polyglutamylated by FPGS and then competes for the DHFR-folate binding site to inhibit dihydrofolate reductase (DHFR)
    • FDA approved for relapsed or refractory, PTCL
    • Recommended dose: 30 mg/m2 IV Q week for 6 weeks with 1 week off for a 7-week treatment cycle. NOTE: Initiate vitamin supplements with folic acid and vitamin B12 IM 2 weeks prior to pralatrexate dose
    • Half-life: 12 to 18 hours
    • Side effects: Edema, fatigue, rash, pruritus, mucositis, constipation, diarrhea, thrombocytopenia, anemia, neutropenia, transaminitis, fever, pain
    Other topics in Targeted and Immunotherapy Agents